Recent clinical features of Wilson?s disease with hepatic presentation

Kumagi, Teru; Horiike, Norio; Michitaka, Kojiro; Hasebe, Aki; Kawai, Keiko; Terada, Yoshio; Nakanishi, Seiji; Furukawa, Shinya; Hiasa, Yoichi; Matsui, Hidetaka; Kurose, Kiyotaka; Matsuura, Bunzo; Onji, Morikazu

doi:10.1007/s00535-004-1466-y

Cited by 52 publications

(51 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In cases 10-16, the HBsAg and HCV antibodies were assayed and found to be negative in each patient (4,(17)(18)(19)(20)(21). In the present case, anti-HCV, HBsAg, and anti-HBc were all negative, and WD was thought to have an etiological relationship with the HCC.…”

Section: Discussionmentioning

confidence: 78%

Hepatocellular Carcinoma in a Case of Wilson's Disease Treated with Radiofrequency Ablation Therapy

et al. 2011

Self Cite

View full text Add to dashboard Cite

A 37-year-old Japanese man was diagnosed with liver cirrhosis due to Wilson's disease in 2001 and treated with D-penicillamine. Thereafter, he was admitted to our hospital for further examination of a space occupying lesion in the liver. The patient was diagnosed with hepatocellular carcinoma (HCC) (7th segment, 2.5 cm in diameter) in May 2010 and treated with radiofrequency ablation therapy. Biopsy findings from a non-cancerous area revealed a fatty liver, though cirrhotic nodules were not found. Long-term treatment for Wilson's disease may improve hepatic fibrosis, and careful screening for HCC by abdominal imaging is needed in such cases.

show abstract

Section: Discussionmentioning

confidence: 78%

Hepatocellular Carcinoma in a Case of Wilson's Disease Treated with Radiofrequency Ablation Therapy

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the role of liver cirrhosis seems to be important in this regard. The common feature shared by all cases with HCC associated with Wilson's diseases was liver cirrhosis (18).…”

Section: Discussionmentioning

confidence: 99%

Small Hepatocellular Carcinoma Associated with Wilson's Disease

et al. 2005

Self Cite

View full text Add to dashboard Cite

show abstract

“…All patients receiving combination therapy became negative for HBV DNA in the sera, whereas, only 56% patients with lamivudine monotherapy lost HBV DNA in the sera within 12 mo. Also, patients with combination therapy did not develop HBV DNA mutation or breakthrough hepatitis [28] .…”

Section: Can Vaccine Therapy Stand the Taste Of Time?mentioning

confidence: 92%

“…Responders: Pol et al [22] (controlled trial) 18.8% HBsAg; 12 times Responders Horiike et al [23] (1 yr: 55%, 2 yr: 77%) PreS2 vaccine; 3 times Responders: 60% Senturk et al [24] S/pre S2; 6 times Decreased HBV DNA Ren et al [25] HBsAg/preS2; 3 times Immune tolerant phage: Dikici et al [26] no significant change PreS2; 3 times anti-HBs; 3 of 31 cases Yalcin et al [27] Combination of lamivudine HBV DNA negativation Horiike et al [28] and HB vaccine in all 15 cases at 1 yr…”

Section: Development Of Hbsag-pulsed DCmentioning

confidence: 99%

Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection

Akbar

Horiike²,

Onji³

2006

WJG

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a global public health problem. Of the approximately 2 billion people who have been infected worldwide, more than 400 million are chronic carriers of HBV. Considerable numbers of chronic HBV carriers suffer from progressive liver diseases. In addition, all HBV carriers are permanent source of this virus. There is no curative therapy for chronic HBV carriers. Antiviral drugs are recommended for about 10% patients, however, these drugs are costly, have limited efficacy, and possess considerable side effects.Recent studies have shown that immune responses of the host to the HBV are critically involved at every stage of chronic HBV infection: (1) These influence acquisition of chronic HBV carrier state, (2) They are important in the context of liver damages, (3) Recovery from chronic HBV-related liver diseases is dependent on nature and extent of HBV-specific immune responses. However, induction of adequate levels of HBV-specific immune responses in chronic HBV carriers is difficult. During the last one decade, hepatitis B vaccine has been administered to chronic HBV carriers as a therapeutic approach (vaccine therapy). The present regimen of vaccine therapy is safe and cheap, but not so effective. A dendritic cell-based therapeutic vaccine has recently been developed for treating chronic HBV infection. In this review, we will discuss about the concept, scientific logics, strategies and techniques of development of HBVspecific immune therapies including vaccine therapy and dendritic cell-based vaccine therapy for treating chronic HBV infection.

show abstract

Recent clinical features of Wilson?s disease with hepatic presentation

Cited by 52 publications

References 12 publications

Hepatocellular Carcinoma in a Case of Wilson's Disease Treated with Radiofrequency Ablation Therapy

Hepatocellular Carcinoma in a Case of Wilson's Disease Treated with Radiofrequency Ablation Therapy

Small Hepatocellular Carcinoma Associated with Wilson's Disease

Immune therapy including dendritic cell based therapy in chronic hepatitis B virus infection

Contact Info

Product

Resources

About